Atezolizumab

About

Therapy type: Immunotherapy

Therapy strategy: PD-1/PD-L1 inhibition

Mappings

NCI Thesaurus: Atezolizumab (ncit:C106250)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 10% TIIC	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	BRAF p.V600E	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (+)	BRAF p.V600K	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
Sensitivity (+)	Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
Sensitivity (+)	Wild type ALK	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel
Sensitivity (+)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab